Resmetirom plus maximally tolerated therapy lowers LDL in heterozygous FH vs. placebo

In patients with heterozygous familial hypercholesterolemia already taking maximally tolerated lipid-lowering medication, resmetirom lowered LDL, triglycerides, apolipoprotein B and lipoprotein(a) levels vs. placebo, researchers reported.
“Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant genetic disorder, with an estimated prevalence of approximately one in 200 to 250, leading to elevated LDL cholesterol plasma levels and increased risk of atherosclerotic coronary vascular disease,” G. Kees Hovingh, MD, professor of internal medicine at the University of

In patients with heterozygous familial hypercholesterolemia already taking maximally tolerated lipid-lowering medication, resmetirom lowered LDL, triglycerides, apolipoprotein B and lipoprotein(a) levels vs. placebo, researchers reported.
“Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant genetic disorder, with an estimated prevalence of approximately one in 200 to 250, leading to elevated LDL cholesterol plasma levels and increased risk of atherosclerotic coronary vascular disease,” G. Kees Hovingh, MD, professor of internal medicine at the University of